Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Opportunities to Optimize Cancer Policies Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Apr

Today In Oncology

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Opportunities to Optimize Cancer Policies Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

AI-Powered, Next-Generation Sequencing Blood-Based Assay Evaluated for Detection of Post-HCT Relapse in AML and MDS

MIBC Pembrolizumab With Trimodal Therapy for Bladder Preservation

Long-Term Outcomes With Taletrectinib in ROS1-Positive NSCLC

Amivantamab in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer

Study Finds Prostate Cancer Overdiagnosis Rises ‘Substantially’ With Age